HomeREGULATORY
REGULATORY

Health Minister Questions How to Gauge Success in Outcome-Based CAR-T Pricing in Japan
(Oct.10.2017)

Health Minister Katsunobu Kato on October 6 questioned how to measure the success in a proposed performance-based pricing model for Novartis AG’s chimeric antigen receptor T cell (CAR-T) therapy Kymriah (tisagenlecleucel), which CEO-elect Vasant Narasimhan reportedly plans to propose to the Japanese government ...
(LOG IN FOR FULL STORY)

News Calendar